ArticleClinical infectious diseases : an official publication of the Infectious Diseases Society of America2021
Superiority of a Novel Mp1p Antigen Detection Enzyme Immunoassay Compared to Standard BACTEC Blood Culture in the Diagnosis of Talaromycosis.
Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 1 synthesis or guideline pooled it, 55 citations in OpenAlex.
- Characteristics of Endemic Mycoses Talaromyces marneffei Infection Associated with Inborn Errors of Immunity.Journal of clinical immunology · 2024Pooled it
- Development and Clinical Evaluation of a Novel Talaromyces marneffei Mp1p Lateral Flow Assay for Rapid Diagnosis of Talaromycosis.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026Article
- Current status and prospects in diagnosis of major opportunistic fungal infections among HIV-positive population in south provinces of China and neighboring countries that are suffering high prevalence of AIDS.Biosafety and health · 2026Review
- Talaromyces marneffei infection of central nervous system in an immunocompetent child in a nonendemic area: a case report and literature review.BMC pediatrics · 2026Review
- Diagnostic performance of a biotin-labeled 4D1 sandwich ELISA for serum antigen detection in talaromycosis.PLoS neglected tropical diseases · 2026Article
- Antigen detection of Talaromyces infection in the US: Case report.Medical mycology case reports · 2026Article
- Clinical Performance of a Mp1p Antibody Detection Immunoassay For Talaromycosis.medRxiv : the preprint server for health sciences · 2026Article
- Recent Advances in the Diagnosis of Talaromycosis.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026Review
- Metagenomic next-generation sequencing improves diagnosis ofFrontiers in medicine · 2026Article
- Comparative performance of a commercial and in-house Mp1p antigen-detecting enzyme immunoassay for the rapid diagnosis of talaromycosis.PLoS neglected tropical diseases · 2025Article
- Practical Guidance for Clinical Microbiology Laboratories: Antibody and antigen detection methods for dimorphic fungal infections.Clinical microbiology reviews · 2025Review
- Advancements in Diagnosing Talaromycosis: Exploring Novel Strategies and Emerging Technologies.Journal of fungi (Basel, Switzerland) · 2025Review
- Optimization and clinical evaluation of a 5.8S rRNA quantitative PCR assay for the diagnosis of talaromycosis.Medical mycology · 2025Article
- An enhancing diagnostic pulmonary diseases diagnostic method for differentiating talaromycosis from tuberculosis.iScience · 2025Article
- An overview of rapid non-culture-based techniques in various clinical specimens for the laboratory diagnosis ofFrontiers in cellular and infection microbiology · 2025Review
- Talaromyces marneffei central nervous system infection unveiled by the novel Mp1p antigen detection assay in AIDS patient.BMC infectious diseases · 2024Article
- A web-based dynamic nomogram for estimating talaromycosis risk in hospitalized HIV-positive patients.Epidemiology and infection · 2024Article
- Excavation of Biomarker Candidates for the Diagnosis ofACS omega · 2024Article
- An evaluation of Mp1p antigen screening for talaromycosis in HIV-infected antiretroviral therapy-naïve population in Guangdong, China.PLoS neglected tropical diseases · 2023Article
- Clinical features of HIV positive talaromycosis marneffei patients and development of a risk prediction model.Heliyon · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 7 institutions in 5 countries.
Funding
Abstract
backgroundTalaromycosis is an invasive mycosis endemic in Southeast Asia and causes substantial morbidity and mortality in individuals with advanced human immunodeficiency virus (HIV) disease. Current diagnosis relies on isolating Talaromyces marneffei in cultures, which takes up to 14 days and is detectable only during late-stage infection, leading to high mortality.
methodsIn this retrospective case-control study, we assessed the accuracy of a novel Mp1p antigen-detecting enzyme immunoassay (EIA) in stored plasma samples of 372 patients who had culture-proven talaromycosis from blood or sterile body fluids (reference standard) and 517 individuals without talaromycosis (338 healthy volunteers; 179 with other infections). All participants were recruited between 2011 and 2017 in Vietnam.
resultsOf cases and controls, 66.1% and 75.4%, respectively, were male; the median age was 33 and 37, respectively. All cases were HIV infected; median CD4 count was 10 cells/μL. At an optical density cutoff of 0.5, the specificity was 98.1% (95% CI, 96.3%-99.0%); the sensitivity was superior to blood culture (86.3% [95% CI, 82.3%-89.5%] vs 72.8% [95% CI, 68.0%-77.2%]) (P < .001, McNemar test). The time to diagnosis was 6 hours vs 6.6 ± 3.0 days for blood culture. Paired plasma and urine testing in the same patients (n = 269) significantly increased sensitivity compared to testing plasma alone or testing urine alone (P < .001 and P = .02, respectively, McNemar test).
conclusionsThe Mp1p EIA is highly specific and is superior in sensitivity and time to diagnosis compared to blood culture for the diagnosis of talaromycosis. Paired plasma and urine testing further increases sensitivity, introducing a new tool for rapid diagnosis, enabling early treatment and potentially reducing mortality.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.